Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MIRUM PHARMACEUTICALS, INC.

(MIRM)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Mirum Pharmaceuticals : Baird Adjusts Mirum Pharmaceuticals PT to $34 From $30, Maintains Outperform Rating

09/30/2021 | 11:16am EST


ę MT Newswires 2021
All news about MIRUM PHARMACEUTICALS, INC.
01/19CANbridge Pharmaceuticals CAN108 New Drug Application (NDA), for Alagille Syndrome, Acc..
AQ
01/12Raymond James Adjusts Mirum Pharmaceuticals Price Target to $70 From $69, Maintains Str..
MT
01/11Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(4)
AQ
01/11MIRUM PHARMACEUTICALS : Provides Business Update and Highlights Key 2022 Corporate Milesto..
PU
01/11MIRUM PHARMACEUTICALS, INC. : Results of Operations and Financial Condition, Regulation FD..
AQ
01/11Mirum Pharmaceuticals Provides Business Update and Highlights Key 2022 Corporate Milest..
BU
01/10Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BU
01/04Mirum Pharmaceuticals to Present at the 40th Annual J.P. Morgan Healthcare Conference o..
BU
01/03Immix Biopharma Shares More Than Double on FDA Designation
DJ
01/03Immix Biopharma Shares Soar Premarket After Key FDA Designation
DJ
More news
Analyst Recommendations on MIRUM PHARMACEUTICALS, INC.
More recommendations
Financials (USD)
Sales 2021 78,4 M - -
Net income 2021 -129 M - -
Net cash 2021 127 M - -
P/E ratio 2021 -3,90x
Yield 2021 -
Capitalization 536 M 536 M -
EV / Sales 2021 5,22x
EV / Sales 2022 10,3x
Nbr of Employees 137
Free-Float -
Chart MIRUM PHARMACEUTICALS, INC.
Duration : Period :
Mirum Pharmaceuticals, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends MIRUM PHARMACEUTICALS, INC.
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 7
Last Close Price 17,60 $
Average target price 54,86 $
Spread / Average Target 212%
EPS Revisions
Managers and Directors
Christopher Peetz President, Chief Executive Officer & Director
Ian Clements Chief Financial Officer
Michael G. Grey Chairman
Pamela Vig Chief Scientific Officer
Edwin J. Tucker Chief Medical Officer
Sector and Competitors
1st jan.Capi. (M$)
MIRUM PHARMACEUTICALS, INC.10.34%536
MODERNA, INC.-36.98%64 900
LONZA GROUP AG-15.65%52 307
IQVIA HOLDINGS INC.-14.60%46 031
SEAGEN INC.-17.50%23 323
ICON PUBLIC LIMITED COMPANY-18.65%20 508